WHO adds first maternal RSV vaccine to prequalification list
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants The World Health Organization (WHO) has announced that it has...
Selected News
UK expands mandatory infectious disease reporting requirements
The update is aimed at strengthening local and national surveillance The UK Health Security Agency (UKHSA) has announced that it...
Orca Bio’s T-cell therapy shows promise in haematological malignancies
The company is preparing to submit the results to the FDA this year Orca Bio has shared promising results from...
UKHSA announces new effort to tackle hepatitis C
The agency has launched a whole genome sequencing service to monitor the virus The UK Health Security Agency (UKHSA) has...
Anocca announces authorisation pancreatic cancer trial
VIDAR-1 trial marks company's clinical-stage debut Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone...
Careology and Entia join forces to transform cancer care
Collaboration brings remote care to cancer patients Careology and Entia have announced a partnership to enhance cancer care through innovative...
Rxulti approved in the European Union for adolescent schizophrenia
EC extends brexpiprazole indication to include adolescents Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved...
Grifols clinical trial shows positive results for post-polio patients
Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating...
Minoryx doses first patient with leriglitazone in Rett syndrome study
Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in its phase...
Orphelia Pharma explores other pathways for paediatric cancer treatment
Company seeks new direction after negative CHMP opinion on KIZFIZO Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after...
Agomab announces positive phase 2a interim results for AGMB-129
FSCD therapy meets all endpoints in interim analysis Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients...
Pfizer’s Talzenna therapy accepted for use within NHS Scotland
Scottish Medicines Consortium approves new option for mCRPC patients Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has...
SECuRE trial pre-chemo participants experience PSA level drops
Cohort expansion phase commences with promising results The Safety Review Committee (SRC) has confirmed the end of the Dose Escalation...
Rotherham NHS Foundation Trust enhances patient engagement
Innovative digital transformation leads to significant improvements To reduce waiting lists and enhance patient communication, Rotherham NHS Foundation Trust has...
Centauri therapeutics selects first ABX-01 clinical candidate
Lead candidate for lung infections moves to human trials Centauri Therapeutics Limited has announced the selection of its first clinical...
Blood cancer patients face treatment access disparity
New research highlights NHS approval gap compared to other cancers Research from the Blood Cancer Alliance reveals a significant disparity...
Datapharm collaborates with VIDAL to improve medicines information access in France
New partnership to integrate SRD search technology Datapharm, a UK-based provider of medicines information, has announced its expansion into Europe...
Brainomix partners with Medtronic to enhance stroke care
New collaboration aims to integrate AI solutions for treatment Brainomix, a leader in stroke AI imaging software, has announced a...
Microbiotica unveils new data on MB097 at AACR IO meeting
Data presented in Los Angeles showcases therapy’s potential Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at...
Mitazalimab shows promising survival rates in cancer study
Updated data from phase 2 study reveals survival benefit Alligator Bioscience has announced updated results from its phase 2 OPTIMIZE-1...
